Eintrag weiter verarbeiten
Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16)
Gespeichert in:
| Zeitschriftentitel: | Blood |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , |
| In: | Blood, 118, 2011, 20, S. 5409-5415 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Hematology
|
| Schlagwörter: |
| author_facet |
Creutzig, Ursula Zimmermann, Martin Bourquin, Jean-Pierre Dworzak, Michael N. von Neuhoff, Christine Sander, Annette Schrauder, André Teigler-Schlegel, Andrea Starý, Jan Corbacioglu, Selim Reinhardt, Dirk Creutzig, Ursula Zimmermann, Martin Bourquin, Jean-Pierre Dworzak, Michael N. von Neuhoff, Christine Sander, Annette Schrauder, André Teigler-Schlegel, Andrea Starý, Jan Corbacioglu, Selim Reinhardt, Dirk |
|---|---|
| author |
Creutzig, Ursula Zimmermann, Martin Bourquin, Jean-Pierre Dworzak, Michael N. von Neuhoff, Christine Sander, Annette Schrauder, André Teigler-Schlegel, Andrea Starý, Jan Corbacioglu, Selim Reinhardt, Dirk |
| spellingShingle |
Creutzig, Ursula Zimmermann, Martin Bourquin, Jean-Pierre Dworzak, Michael N. von Neuhoff, Christine Sander, Annette Schrauder, André Teigler-Schlegel, Andrea Starý, Jan Corbacioglu, Selim Reinhardt, Dirk Blood Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16) Cell Biology Hematology Immunology Biochemistry |
| author_sort |
creutzig, ursula |
| spelling |
Creutzig, Ursula Zimmermann, Martin Bourquin, Jean-Pierre Dworzak, Michael N. von Neuhoff, Christine Sander, Annette Schrauder, André Teigler-Schlegel, Andrea Starý, Jan Corbacioglu, Selim Reinhardt, Dirk 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood-2011-07-364661 <jats:title>Abstract</jats:title> <jats:p>Patients with core binding factor acute myeloid leukemia (CBF-AML) benefit from more intensive chemotherapy, but whether both the t(8;21) and inv(16)/t (16;16) subtypes requires intensification remained to be determined. In the 2 successive studies (AML-BFM-1998 and AML-BFM-2004), 220 CBF-AML patients were treated using the same chemotherapy backbone, whereby reinduction with high-dose cytarabine and mitoxantrone (HAM) was scheduled for these cohorts only in study AML-BFM-1998 but not in AML-BFM-2004 against the background to minimize overtreatment. Five-year overall survival (OS) and event-free survival (EFS) were significantly higher and the cumulative incidence of relapse (CIR) lower in t(8;21) patients treated with HAM (n = 78) compared with without HAM (n = 53): OS 92% ± 3% versus 80% ± 6%, plogrank0.047, EFS 84% ± 4% versus 59% ± 7%, plogrank0.001, and CIR 14% ± 4% versus 34% ± 7%, p(gray)0.006. These differences were not seen for inv(16) (n = 43 and 46, respectively): OS 93% ± 4% versus 94% ± 4%, EFS 75% ± 7% versus 71% ± 9% and CIR 15% ± 6% versus 23% ± 8% (not significant). The subtype t(8;21), but not inv(16), was an independent predictor of worse outcome without HAM reinduction. Based on our data, a 5-year OS of > 90% can be expected for CBF-AML, when stratifying t(8;21), but not inv(16), patients to high-risk chemotherapy, including HAM reinduction.</jats:p> Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16) Blood |
| doi_str_mv |
10.1182/blood-2011-07-364661 |
| facet_avail |
Online Free |
| finc_class_facet |
Biologie Medizin Chemie und Pharmazie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDExLTA3LTM2NDY2MQ |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDExLTA3LTM2NDY2MQ |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
American Society of Hematology, 2011 |
| imprint_str_mv |
American Society of Hematology, 2011 |
| issn |
0006-4971 1528-0020 |
| issn_str_mv |
0006-4971 1528-0020 |
| language |
English |
| mega_collection |
American Society of Hematology (CrossRef) |
| match_str |
creutzig2011secondinductionwithhighdosecytarabineandmitoxantronedifferentimpactonpediatricamlpatientswitht821andwithinv16 |
| publishDateSort |
2011 |
| publisher |
American Society of Hematology |
| recordtype |
ai |
| record_format |
ai |
| series |
Blood |
| source_id |
49 |
| title |
Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16) |
| title_unstemmed |
Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16) |
| title_full |
Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16) |
| title_fullStr |
Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16) |
| title_full_unstemmed |
Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16) |
| title_short |
Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16) |
| title_sort |
second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric aml patients with t(8;21) and with inv(16) |
| topic |
Cell Biology Hematology Immunology Biochemistry |
| url |
http://dx.doi.org/10.1182/blood-2011-07-364661 |
| publishDate |
2011 |
| physical |
5409-5415 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>Patients with core binding factor acute myeloid leukemia (CBF-AML) benefit from more intensive chemotherapy, but whether both the t(8;21) and inv(16)/t (16;16) subtypes requires intensification remained to be determined. In the 2 successive studies (AML-BFM-1998 and AML-BFM-2004), 220 CBF-AML patients were treated using the same chemotherapy backbone, whereby reinduction with high-dose cytarabine and mitoxantrone (HAM) was scheduled for these cohorts only in study AML-BFM-1998 but not in AML-BFM-2004 against the background to minimize overtreatment. Five-year overall survival (OS) and event-free survival (EFS) were significantly higher and the cumulative incidence of relapse (CIR) lower in t(8;21) patients treated with HAM (n = 78) compared with without HAM (n = 53): OS 92% ± 3% versus 80% ± 6%, plogrank0.047, EFS 84% ± 4% versus 59% ± 7%, plogrank0.001, and CIR 14% ± 4% versus 34% ± 7%, p(gray)0.006. These differences were not seen for inv(16) (n = 43 and 46, respectively): OS 93% ± 4% versus 94% ± 4%, EFS 75% ± 7% versus 71% ± 9% and CIR 15% ± 6% versus 23% ± 8% (not significant). The subtype t(8;21), but not inv(16), was an independent predictor of worse outcome without HAM reinduction. Based on our data, a 5-year OS of > 90% can be expected for CBF-AML, when stratifying t(8;21), but not inv(16), patients to high-risk chemotherapy, including HAM reinduction.</jats:p> |
| container_issue |
20 |
| container_start_page |
5409 |
| container_title |
Blood |
| container_volume |
118 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792337910914088960 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T15:23:51.863Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Second+induction+with+high-dose+cytarabine+and+mitoxantrone%3A+different+impact+on+pediatric+AML+patients+with+t%288%3B21%29+and+with+inv%2816%29&rft.date=2011-11-17&genre=article&issn=1528-0020&volume=118&issue=20&spage=5409&epage=5415&pages=5409-5415&jtitle=Blood&atitle=Second+induction+with+high-dose+cytarabine+and+mitoxantrone%3A+different+impact+on+pediatric+AML+patients+with+t%288%3B21%29+and+with+inv%2816%29&aulast=Reinhardt&aufirst=Dirk&rft_id=info%3Adoi%2F10.1182%2Fblood-2011-07-364661&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792337910914088960 |
| author | Creutzig, Ursula, Zimmermann, Martin, Bourquin, Jean-Pierre, Dworzak, Michael N., von Neuhoff, Christine, Sander, Annette, Schrauder, André, Teigler-Schlegel, Andrea, Starý, Jan, Corbacioglu, Selim, Reinhardt, Dirk |
| author_facet | Creutzig, Ursula, Zimmermann, Martin, Bourquin, Jean-Pierre, Dworzak, Michael N., von Neuhoff, Christine, Sander, Annette, Schrauder, André, Teigler-Schlegel, Andrea, Starý, Jan, Corbacioglu, Selim, Reinhardt, Dirk, Creutzig, Ursula, Zimmermann, Martin, Bourquin, Jean-Pierre, Dworzak, Michael N., von Neuhoff, Christine, Sander, Annette, Schrauder, André, Teigler-Schlegel, Andrea, Starý, Jan, Corbacioglu, Selim, Reinhardt, Dirk |
| author_sort | creutzig, ursula |
| container_issue | 20 |
| container_start_page | 5409 |
| container_title | Blood |
| container_volume | 118 |
| description | <jats:title>Abstract</jats:title> <jats:p>Patients with core binding factor acute myeloid leukemia (CBF-AML) benefit from more intensive chemotherapy, but whether both the t(8;21) and inv(16)/t (16;16) subtypes requires intensification remained to be determined. In the 2 successive studies (AML-BFM-1998 and AML-BFM-2004), 220 CBF-AML patients were treated using the same chemotherapy backbone, whereby reinduction with high-dose cytarabine and mitoxantrone (HAM) was scheduled for these cohorts only in study AML-BFM-1998 but not in AML-BFM-2004 against the background to minimize overtreatment. Five-year overall survival (OS) and event-free survival (EFS) were significantly higher and the cumulative incidence of relapse (CIR) lower in t(8;21) patients treated with HAM (n = 78) compared with without HAM (n = 53): OS 92% ± 3% versus 80% ± 6%, plogrank0.047, EFS 84% ± 4% versus 59% ± 7%, plogrank0.001, and CIR 14% ± 4% versus 34% ± 7%, p(gray)0.006. These differences were not seen for inv(16) (n = 43 and 46, respectively): OS 93% ± 4% versus 94% ± 4%, EFS 75% ± 7% versus 71% ± 9% and CIR 15% ± 6% versus 23% ± 8% (not significant). The subtype t(8;21), but not inv(16), was an independent predictor of worse outcome without HAM reinduction. Based on our data, a 5-year OS of > 90% can be expected for CBF-AML, when stratifying t(8;21), but not inv(16), patients to high-risk chemotherapy, including HAM reinduction.</jats:p> |
| doi_str_mv | 10.1182/blood-2011-07-364661 |
| facet_avail | Online, Free |
| finc_class_facet | Biologie, Medizin, Chemie und Pharmazie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDExLTA3LTM2NDY2MQ |
| imprint | American Society of Hematology, 2011 |
| imprint_str_mv | American Society of Hematology, 2011 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 0006-4971, 1528-0020 |
| issn_str_mv | 0006-4971, 1528-0020 |
| language | English |
| last_indexed | 2024-03-01T15:23:51.863Z |
| match_str | creutzig2011secondinductionwithhighdosecytarabineandmitoxantronedifferentimpactonpediatricamlpatientswitht821andwithinv16 |
| mega_collection | American Society of Hematology (CrossRef) |
| physical | 5409-5415 |
| publishDate | 2011 |
| publishDateSort | 2011 |
| publisher | American Society of Hematology |
| record_format | ai |
| recordtype | ai |
| series | Blood |
| source_id | 49 |
| spelling | Creutzig, Ursula Zimmermann, Martin Bourquin, Jean-Pierre Dworzak, Michael N. von Neuhoff, Christine Sander, Annette Schrauder, André Teigler-Schlegel, Andrea Starý, Jan Corbacioglu, Selim Reinhardt, Dirk 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood-2011-07-364661 <jats:title>Abstract</jats:title> <jats:p>Patients with core binding factor acute myeloid leukemia (CBF-AML) benefit from more intensive chemotherapy, but whether both the t(8;21) and inv(16)/t (16;16) subtypes requires intensification remained to be determined. In the 2 successive studies (AML-BFM-1998 and AML-BFM-2004), 220 CBF-AML patients were treated using the same chemotherapy backbone, whereby reinduction with high-dose cytarabine and mitoxantrone (HAM) was scheduled for these cohorts only in study AML-BFM-1998 but not in AML-BFM-2004 against the background to minimize overtreatment. Five-year overall survival (OS) and event-free survival (EFS) were significantly higher and the cumulative incidence of relapse (CIR) lower in t(8;21) patients treated with HAM (n = 78) compared with without HAM (n = 53): OS 92% ± 3% versus 80% ± 6%, plogrank0.047, EFS 84% ± 4% versus 59% ± 7%, plogrank0.001, and CIR 14% ± 4% versus 34% ± 7%, p(gray)0.006. These differences were not seen for inv(16) (n = 43 and 46, respectively): OS 93% ± 4% versus 94% ± 4%, EFS 75% ± 7% versus 71% ± 9% and CIR 15% ± 6% versus 23% ± 8% (not significant). The subtype t(8;21), but not inv(16), was an independent predictor of worse outcome without HAM reinduction. Based on our data, a 5-year OS of > 90% can be expected for CBF-AML, when stratifying t(8;21), but not inv(16), patients to high-risk chemotherapy, including HAM reinduction.</jats:p> Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16) Blood |
| spellingShingle | Creutzig, Ursula, Zimmermann, Martin, Bourquin, Jean-Pierre, Dworzak, Michael N., von Neuhoff, Christine, Sander, Annette, Schrauder, André, Teigler-Schlegel, Andrea, Starý, Jan, Corbacioglu, Selim, Reinhardt, Dirk, Blood, Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16), Cell Biology, Hematology, Immunology, Biochemistry |
| title | Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16) |
| title_full | Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16) |
| title_fullStr | Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16) |
| title_full_unstemmed | Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16) |
| title_short | Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16) |
| title_sort | second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric aml patients with t(8;21) and with inv(16) |
| title_unstemmed | Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16) |
| topic | Cell Biology, Hematology, Immunology, Biochemistry |
| url | http://dx.doi.org/10.1182/blood-2011-07-364661 |